'We deserve answers': Sen. Murray grills NIH chief over terminated cancer trials at fiery hearing

NIH Oversight Hearing: Disruptions to Clinical Trials & Research Policies

Key Concepts:

• NIH Grant Terminations/Freezes: The abrupt ending or suspension of financial support for National Institutes of Health (NIH) funded research projects.
• Clinical Trials: Research studies involving human volunteers designed to evaluate the safety and effectiveness of medical interventions.
• Advisory Councils: Committees mandated by law to provide guidance to NIH before grant awards, ensuring transparency and expert review.
• Fetal Tissue Research: Utilizing tissue from elective abortions for medical research, a practice with significant ethical and scientific debate.
• Gain-of-Function Research: Scientific modification of a pathogen to increase its transmissibility or virulence, raising biosafety concerns.
• EcoHealth Alliance: A non-profit organization involved in research on emerging infectious diseases, specifically linked to NIH funding of research at the Wuhan Institute of Virology.
• Continuity of Care: Ensuring uninterrupted medical treatment for patients participating in clinical trials, even during disruptions.

I. Disruption of NIH-Funded Clinical Trials Under the Trump Administration

The hearing focused heavily on the impact of grant terminations and freezes initiated by the Trump administration on NIH-funded clinical trials. Senator Murray opened by stating that one in 30 NIH-funded clinical trials were disrupted last year, affecting over 74,000 participants. Specifically, 383 active clinical trials were terminated in under six months, including 118 focused on cancer.

A key point of contention was the scale of these terminations. Senator Murray cited a total of 5,478 NIH grants terminated or frozen. Dr. Bareria, representing NIH, asserted that efforts were made to ensure continuity of care for patients impacted by these disruptions and that trials were “renegotiated,” suggesting a lower final number of terminated trials – “maybe only a dozen.” This discrepancy in figures drew criticism from Senator Murray, who emphasized the urgency for patients “in a race for time.”

II. Advisory Council Disbandment and Funding Delays

The hearing also addressed concerns regarding the dismantling of NIH advisory councils. It was revealed that all NIH institutes and centers were prohibited from holding advisory council meetings last year, hindering the grant award process as these meetings are legally required before funding can be approved.

Furthermore, advisory council members were not being replaced at the end of their terms, and the Advisory Committee to the Director – a crucial body in NIH’s 139-year history – was completely disbanded and hadn’t met in over a year. More than half of NIH institutes are projected to lose all voting advisory committee members by the end of 2026, with one institute facing complete membership loss by the end of the current month. This situation poses a “very serious threat” to NIH’s ability to fund research due to the legal requirement for council approval.

Dr. Bareria stated that nominations for new members were underway and that the institutes were working “as fast as we can” to restore council functionality, promising “no delay.” However, Senator Murray pressed for a detailed timeline and status report on all councils.

III. Ban on Fetal Tissue Research & its Implications

NIH’s recent ban on fetal tissue research was another major point of discussion. This policy halted research that has contributed to significant medical advancements, including the polio vaccine and IVF. Senator Murray argued that the ban halts “irreplaceable research” into treatments for diseases like Alzheimer’s and Parkinson’s.

Dr. Bareria defended the ban by stating that the use of fetal tissue in research has been declining due to the availability of alternatives like induced pluripotent stem cells and other new technologies. However, Senator Murray challenged this claim, pointing out the limited availability of truly comparable alternatives, particularly in stem cell research. She characterized the decision as “political,” noting its timing coincided with a gathering of anti-abortion activists in DC.

The ban is projected to affect upwards of 600 NIH projects totaling $325 million. Dr. Bareria committed to providing a complete list of affected projects to the committee. He clarified that the policy aimed to encourage scientists to find alternatives rather than outright terminating projects, stating that using tissue from aborted embryos is “not necessary for science.”

IV. Oversight of Funding to the Wuhan Institute of Virology & Gain-of-Function Research

Senator Paul raised concerns about NIH’s past funding of gain-of-function research at the Wuhan Institute of Virology through the EcoHealth Alliance. He highlighted that NIH initially denied funding this research, only to later admit it after public reporting. He accused NIH of misleading the American public and labeled those who questioned the funding as “conspiracy theorists.”

Dr. Bareria stated that his primary focus has been on preventing future funding of potentially dangerous gain-of-function research, pausing 40 grants with potential risks and implementing new oversight policies for foreign collaborations. He acknowledged that a comprehensive review of all NIH funding to Wuhan and other Chinese labs is underway but described it as a “long, long review” involving multiple agencies and foreign partners. He could not provide a completion date for the review.

V. Logical Connections & Data

The hearing demonstrated a clear connection between policy decisions made under the previous administration and their potential negative consequences for medical research and patient care. The data presented – 1 in 30 trials disrupted, 74,000+ participants affected, 383 trials terminated, 5,478 grants frozen, $325 million in projects impacted by the fetal tissue ban – underscored the significant scale of these disruptions. The discussion regarding the Wuhan Institute of Virology highlighted the importance of transparency and accountability in funding scientific research, particularly when dealing with potentially dangerous pathogens.

Conclusion:

The hearing revealed significant concerns regarding disruptions to NIH-funded research under the previous administration, stemming from grant terminations, advisory council disbandment, and policy changes like the ban on fetal tissue research. The lack of clear answers and guarantees from Dr. Bareria regarding future funding decisions and the completion of the review of funding to Chinese labs fueled skepticism among committee members. The central takeaway is the need for greater transparency, accountability, and a commitment to ensuring the continuity of vital medical research for the benefit of patients and public health.